（编辑 袁冠琳） 证券日报网讯 国药一致9月3日发布公告，在公司回答调研者提问时表示，公司对分销的整体预期是与 去年基本持平。集采扩面、支付改革对利润率的压力客观存在，但集采商品的回款周期将会缩短。此 外，公司有效填补缺口的模式是国产和进口新药的上市速度变快，医保也给予适当通路。同时，公司也 在持续推动医院的SPD项目的推广，目前成效较好。 ...

Core Viewpoint - The company reported a significant decline in operating cash flow for the first half of the year, primarily due to extended payment terms in its distribution business and negative sales growth in Guoda Pharmacy [1] Group 1 - The operating cash flow decreased year-on-year, indicating potential liquidity issues for the company [1] - Extended payment terms in the distribution business have negatively impacted cash flow [1] - Guoda Pharmacy experienced a decline in sales revenue, contributing to reduced positive cash flow [1]

证券日报网讯 国药一致9月3日发布公告，在公司回答调研者提问时表示，广西市场，根据已经披露的 半年报来看，广西公司与主要竞争对手差距越来越小，公司在广西市场的市占率有所提升。广东市场， 主要对手的整体规模仍保持正增长，但本公司净利润率远高于对方，而且我们在公立医院市场的份额仍 保持增长，保持良好的竞争态势。等市场环境好转后，公司会继续扩大相应的市场份额。 （编辑 袁冠琳） ...

Core Viewpoint - China National Pharmaceutical Group announced on September 3 that its subsidiary, Guoda Pharmacy, has improved profitability in the first half of the year through various measures, indicating positive financial performance [1] Summary by Categories Profitability Improvement - Guoda Pharmacy has implemented several initiatives to enhance its profitability, which have shown effective results [1] - Key strategies include the development of high-margin proprietary brand products and strengthening centralized procurement to optimize gross margins [1] - The pharmacy has also achieved cost savings through intensive management practices, contributing to overall profit growth [1]

证券日报网讯 国药一致9月3日发布公告，在公司回答调研者提问时表示，从行业平均水平来看，净利 润率大概处在中低个位数。过往国大药房的净利润偏低，主要还是与其产品结构有关，公司将会通过产 品品类优化进一步改善毛利率，通过费用节约，进而改善净利率，公司认为还有一定空间。 （编辑 袁冠琳） ...

Group 1 - The core viewpoint of the article highlights that the O2O (Online to Offline) business model is expanding opportunities for physical pharmacies, but the platform service fees are impacting their profitability [1] - The company, Guoda Pharmacy, is actively communicating and coordinating with various platform enterprises to seek cost savings amid competition [1] - O2O is recognized as a trend in the industry, prompting physical pharmacies to maintain their uniqueness to cope with pricing pressures from online products [1]

Core Viewpoint - The company anticipates stable distribution performance despite pressure from medical insurance cost control and procurement expansion, with new drug launches and effective hospital projects providing growth opportunities [1]. Distribution Segment Performance Expectations - The company expects distribution performance to remain flat compared to last year due to medical insurance cost control, although the collection cycle for procured products has shortened [1]. - The introduction of both domestic and imported new drugs is accelerating, supported by medical insurance channels and successful promotion of hospital SPD projects [1]. Strategic Focus on Narcotic Drugs - The company will enhance its efforts in obtaining narcotic qualifications and improve internal coordination of narcotic product resources with the national distribution platform [2]. Market Outlook in Guangxi and Guangdong - In Guangxi, the company has narrowed the gap with major competitors and increased market share [3]. - In Guangdong, while competitors are growing, the company maintains a significantly higher net profit margin and continues to grow its market share in public hospitals [3]. Response to Procurement and New Growth Points - The company has faced credit impairment losses and investment income impacts but has not been fundamentally affected by procurement policies [4]. - New product launches and the growth of specialty pharmacies are expected to alleviate pressure on profits [4]. Increase in Credit Impairment Losses - The rise in credit impairment losses is attributed to extended collection periods for accounts receivable, leading to increased aging and scale [5]. Retail Segment Development Strategy - The company has no plans for large-scale store closures in the second half of the year and is adapting its business model in response to online competition [6]. Profit Growth of Guoda Pharmacy - Guoda Pharmacy achieved profit growth through store closures, cost rate adjustments, and centralized management [7]. Decline in Operating Cash Flow - The decline in operating cash flow is due to extended collection periods in the distribution business and negative sales growth at Guoda Pharmacy [8]. Industry Development Judgement - The pharmacy industry is becoming increasingly important in medical circulation, with short-term policy impacts slowing growth but maintaining significant social value in the long term [9]. M&A Expectations in the Pharmacy Sector - Guoda Pharmacy is currently focused on stability and efficiency improvements, with no short-term acquisition plans, but may consider expansion in the future once the industry stabilizes [10]. Retail Segment Net Profit Margin Goals - The average net profit margin in the industry is in the low single digits, and Guoda Pharmacy aims to improve its margin through product optimization and cost savings [13]. O2O Business Expansion - The company is expanding its O2O business but faces profitability challenges due to platform service fees, while maintaining its unique positioning to counter online pricing pressures [14]. Store and Supply Chain Adjustments - The company is adjusting its store formats and supply chain services in response to medical insurance policy changes, prioritizing the health sector [15]. Goodwill Impairment Risk - The company conducts annual goodwill impairment tests, with current conditions remaining stable, and specific results pending further testing [16]. Digital Transformation and Smart Logistics - The company is enhancing efficiency and reducing labor costs through investments in automation and IT systems, resulting in lower sales and management expenses [17]. Dividend Policy - The company committed to a minimum dividend payout ratio of 20% over three years, with this year's payout exceeding 30% [18]. Accounts Receivable Management - The company plans to strengthen credit management in the second half of the year, implementing dual controls on payment terms and limits to reduce high-risk business [19]. "14th Five-Year" Planning Review - The company is preparing for its "15th Five-Year" plan, reflecting on the implementation of the previous plan and focusing on optimizing business and management structures [20]. Revenue and Profit Outlook for the Year - The company expects stable revenue performance despite intense market competition, emphasizing the balance between accounts receivable and sales revenue to ensure quality [21].

Group 1: Financial Performance and Market Outlook - The company expects overall performance in the distribution sector to remain stable compared to last year, despite pressures from centralized procurement and payment reforms [2] - The net profit margin in the Guangdong market is significantly higher than competitors, with continued growth in public hospital market share [2] - The company has seen a substantial increase in credit impairment losses due to extended receivable collection periods and increased receivable scales [3] Group 2: Strategic Initiatives and Business Development - The company plans to enhance its capabilities in narcotic and psychotropic drug qualifications and improve internal collaboration for resource distribution [2] - There is a focus on accelerating the launch of new domestic and imported drugs to fill market gaps, alongside promoting hospital SPD projects [2] - The company is committed to digital transformation and smart logistics, which are expected to yield measurable cost savings and efficiency improvements [4] Group 3: Retail and Distribution Strategy - The company does not plan large-scale store closures in the near term, but is adapting to online sales pressures by enhancing product offerings and operational efficiency [3] - The retail sector's net profit margin is targeted to improve towards 3%, with strategies to optimize product categories and reduce costs [3] - The company emphasizes the importance of retail pharmacies in the pharmaceutical distribution chain, despite short-term pressures from regulatory changes [3] Group 4: Future Planning and Risk Management - The company is reviewing its "14th Five-Year Plan" and preparing for the "15th Five-Year Plan," focusing on market changes and organizational adjustments [4] - There is a commitment to maintaining a dividend policy of at least 20%, with current payouts exceeding 30% [4] - The company is enhancing its management of accounts receivable to ensure a reasonable return to levels, focusing on high-risk clients and overdue accounts [4]

Summary of the Conference Call for Guoyao Yizhi Company Overview - **Company**: Guoyao Yizhi - **Period**: First half of 2025 Key Financial Performance - Total revenue decreased by 2.62% to 36.797 billion yuan [3] - Net profit attributable to shareholders fell by 10.43% to 666 million yuan [3] - Total assets increased slightly to 550.426 billion yuan, with a stable debt ratio of 57.86% [3] - Earnings per share decreased by 10% to 1.2 yuan [3] - Operating cash flow declined significantly, attributed to extended receivables and negative sales growth in retail [15][16] Distribution Segment Performance - Distribution revenue decreased by 1.09% to 26.783 billion yuan, with net profit down by 7.82% [5] - High-margin products such as biological products, narcotic drugs, and innovative drugs showed strong growth [5] - Collaboration in the Hong Kong and Macau regions was emphasized, along with the integration of new products and innovative drug business [5] - The company expects distribution segment performance to remain stable compared to 2024, despite pressures from procurement expansion and healthcare payment reforms [9] Retail Segment Performance - Retail revenue from Guoda Pharmacy decreased by 6.46% to 10.479 billion yuan, but net profit surged by 215.81% to 17 million yuan [5] - The improvement in net profit was due to continuous optimization of product structure and business model, as well as enhanced operational efficiency [5] - Approximately 1,000 stores were closed to optimize layout, resulting in a total of 8,591 stores by the end of June 2025 [8] Digital Transformation and Smart Logistics - The company implemented digital tools to enhance operational efficiency and management [6] - A "1+4+N" warehouse network layout was established to improve storage capacity and efficiency [6] Organizational Changes and Talent Development - Organizational restructuring was undertaken to enhance resource integration and talent development [7] - Performance and incentive mechanisms were optimized to align with company goals [7] Credit Impairment Losses - Credit impairment losses increased significantly due to extended payment terms and high revenue scale [12] - The company plans to strengthen credit management and control high-risk clients [12][25] Future Strategies and Market Outlook - The company aims to expand its narcotic qualifications and enhance regional coverage [10] - Confidence in increasing market share in Guangxi and Guangdong, despite competitive pressures [11][18] - Focus on improving operational quality and cash flow management in a competitive environment [18] Industry Trends and Challenges - The retail pharmacy sector is expected to face challenges due to increased management and competition, but long-term value remains [17] - The company will continue to adapt to market changes and enhance operational capabilities [17] Conclusion - Guoyao Yizhi is navigating a challenging environment with a focus on optimizing operations, enhancing digital capabilities, and maintaining a stable market presence while addressing credit risks and adapting to industry changes. The outlook remains cautiously optimistic with strategic initiatives aimed at improving profitability and market share.

Investment Rating - The investment rating for the company is maintained at "Buy" with a target price of RMB 31.31 [1][5][6] Core Views - The company's performance in the first half of 2025 is under pressure due to industry policy changes, intensified market competition, and extended customer payment cycles, leading to a year-on-year decline in revenue and net profit [1][2] - Despite the short-term challenges, the company is expected to improve its performance as the effects of its high-quality development strategy become evident [1][5] - The company is focusing on enhancing its distribution and retail segments, particularly through the integration of innovative drug businesses and the expansion of its self-owned brand [2][3] Summary by Sections Distribution - In the first half of 2025, distribution revenue was RMB 267.83 billion, down 1.09% year-on-year, with net profit decreasing by 7.82% to RMB 4.82 billion [2] - The decline in net profit is attributed to increased long-term accounts receivable due to delayed payments from downstream customers, leading to higher bad debt provisions [2] - The company is accelerating the integration of its narcotic and psychotropic drug business, with notable sales growth in specific segments [2] Retail - The retail segment, represented by Guoda Pharmacy, reported revenue of RMB 104.79 million, a decrease of 6.46% year-on-year, while net profit increased significantly by 215.81% to RMB 0.17 million [3] - The company is optimizing its business structure and enhancing profitability through self-owned brand development and strategic store closures [3] - The gross margin for Guoda Pharmacy's direct sales improved by 1.25 percentage points year-on-year due to effective procurement cost optimization [3] Financial Metrics - The overall expense ratio for the company decreased year-on-year, while the gross margin slightly declined to 10.69% [4] - The company forecasts a decline in wholesale and retail business revenue expectations, with projected net profits for 2025-2027 being RMB 13.52 billion, RMB 13.78 billion, and RMB 14.00 billion respectively [5][7] - The estimated EPS for 2025 is RMB 2.43, with a corresponding PE ratio of 10.62 [7]